Look Under The Hood: FXH Has 16% Upside
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2024
0mins
Source: NASDAQ.COM
- Analyst Target Prices for ETFs: Analysts have calculated the implied target price for the First Trust Health Care AlphaDEX Fund ETF (FXH) to be $123.87 per unit, indicating a 15.67% upside from its current trading price of $107.09 per unit.
- Stock Analysis and Investor Considerations: The article discusses the analyst target prices for specific holdings within FXH, such as Sarepta Therapeutics Inc, Envista Holdings Corp, and Zoetis Inc, highlighting potential upsides and the importance of investor research in evaluating these targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 77.560
Low
130.00
Averages
154.20
High
200.00
Current: 77.560
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of securities laws, concerning trades from January 14, 2025, to May 6, 2026, with a deadline to contact the firm by July 27, 2026, for participation.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products also suffered from newly launched competing treatments, exacerbating the company's market challenges.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act will remain absent class members, potentially facing greater financial risks.
See More
Zoetis Investors Reminder: Lawsuit Deadline Approaches
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion in the securities fraud lawsuit against Zoetis Inc. is July 27, 2026, requiring investors to act promptly to participate.
- Declining Financial Performance: On August 5, 2025, Zoetis reported weakened demand in its Companion Animal portfolio, resulting in a 3.8% drop in stock price to $146.12 per share, which negatively impacted investor confidence.
- Increased Market Competition: On May 7, 2026, Zoetis announced slowing overall revenue growth and declining sales in its Companion Animal segment, leading to a significant 21.5% stock price drop to $87.31 per share, highlighting the company's struggles in a competitive market.
- Allegations of Misleading Statements: The lawsuit alleges that defendants made materially false statements and failed to disclose adverse facts about the company's operations, resulting in investor losses and raising concerns about the company's future prospects.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Deadline: Zoetis Inc. faces a securities fraud class action lawsuit with a deadline of July 27, 2026, for investors to submit necessary documents to participate, while those who do not act will remain absent class members and may lose their chance for recovery.
- Investor Losses: The lawsuit targets investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company and its executives made materially false and misleading statements regarding business operations, growth prospects, and financial stability, resulting in artificially inflated stock prices.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strength in investor rights protection.
- No Fee Representation: The lawsuit operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to take action.
See More
Class Action Lawsuit Filed Against Zoetis Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Declining Market Share: The lawsuit claims that veterinarian prescription growth and adoption of Zoetis' flagship product Librela have sharply weakened due to FDA safety warnings regarding serious neurological complications in dogs, which could adversely affect the company's future revenue.
- Increased Competition: Zoetis' Simparica Trio is reportedly losing significant market share to a lower-priced competing canine parasiticide with broader indications, reflecting a trend of overall market slowdown that may impact the company's competitive position.
- Product Market Challenges: The lawsuit also indicates that Zoetis' dermatology products, Apoquel and Cytopoint, are facing strong competition from newly launched alternatives, resulting in substantial market share losses and increasing business pressure on the company.
See More
Zoetis Faces Class Action Over Risk Disclosures
- Significant Stock Decline: Zoetis shares plummeted from $151.81 to $87.31, indicating a severe loss of investor confidence due to the company's failure to adequately disclose risks, which could impair future capital raising efforts.
- Legal Action Context: A securities class action against Zoetis alleges that the company misrepresented the risks associated with its products between January 14, 2025, and May 6, 2026, potentially leading to investor losses and increasing legal risks for the firm.
- Disclosure Deficiencies: The lawsuit claims that Zoetis failed to communicate a significant decline in veterinarian prescription intent for Librela following FDA safety warnings, despite management's assertions of “very strong” customer satisfaction, highlighting a lack of transparency in the face of real market challenges.
- Regulatory Letter Impact: The FDA's letter described severe adverse neurological events linked to Librela, yet Zoetis management characterized it as “terribly helpful,” a contradictory statement that may further erode investor trust.
See More
Zoetis Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP reminds investors of a class action filed against Zoetis Inc. (NYSE: ZTS) for securities purchased between January 14, 2025, and May 6, 2026, alleging failure to disclose critical product performance issues that led to investor losses.
- Market Share Decline: The complaint indicates that Zoetis' Librela and Simparica Trio products lost market share due to slowing veterinarian prescription growth, compounded by FDA safety warnings and competition from lower-priced alternatives, adversely affecting the company's core business.
- Deteriorating Financial Results: In its Q1 2026 financial report, Zoetis revealed significant deterioration in its core Companion Animal business and sharply reduced its full-year guidance, resulting in a 21.5% stock price drop on May 7, 2026.
- Investor Action: Affected shareholders can submit documents by July 27, 2026, to serve as lead plaintiffs in the class action, with Robbins LLP offering contingency fee representation, ensuring no upfront costs for shareholders.
See More
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of securities laws, concerning trades from January 14, 2025, to May 6, 2026, with a deadline to contact the firm by July 27, 2026, for participation.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products also suffered from newly launched competing treatments, exacerbating the company's market challenges.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act will remain absent class members, potentially facing greater financial risks.
See More
Zoetis Investors Reminder: Lawsuit Deadline Approaches
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion in the securities fraud lawsuit against Zoetis Inc. is July 27, 2026, requiring investors to act promptly to participate.
- Declining Financial Performance: On August 5, 2025, Zoetis reported weakened demand in its Companion Animal portfolio, resulting in a 3.8% drop in stock price to $146.12 per share, which negatively impacted investor confidence.
- Increased Market Competition: On May 7, 2026, Zoetis announced slowing overall revenue growth and declining sales in its Companion Animal segment, leading to a significant 21.5% stock price drop to $87.31 per share, highlighting the company's struggles in a competitive market.
- Allegations of Misleading Statements: The lawsuit alleges that defendants made materially false statements and failed to disclose adverse facts about the company's operations, resulting in investor losses and raising concerns about the company's future prospects.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Deadline: Zoetis Inc. faces a securities fraud class action lawsuit with a deadline of July 27, 2026, for investors to submit necessary documents to participate, while those who do not act will remain absent class members and may lose their chance for recovery.
- Investor Losses: The lawsuit targets investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company and its executives made materially false and misleading statements regarding business operations, growth prospects, and financial stability, resulting in artificially inflated stock prices.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strength in investor rights protection.
- No Fee Representation: The lawsuit operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to take action.
See More
Class Action Lawsuit Filed Against Zoetis Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Declining Market Share: The lawsuit claims that veterinarian prescription growth and adoption of Zoetis' flagship product Librela have sharply weakened due to FDA safety warnings regarding serious neurological complications in dogs, which could adversely affect the company's future revenue.
- Increased Competition: Zoetis' Simparica Trio is reportedly losing significant market share to a lower-priced competing canine parasiticide with broader indications, reflecting a trend of overall market slowdown that may impact the company's competitive position.
- Product Market Challenges: The lawsuit also indicates that Zoetis' dermatology products, Apoquel and Cytopoint, are facing strong competition from newly launched alternatives, resulting in substantial market share losses and increasing business pressure on the company.
See More
Zoetis Faces Class Action Over Risk Disclosures
- Significant Stock Decline: Zoetis shares plummeted from $151.81 to $87.31, indicating a severe loss of investor confidence due to the company's failure to adequately disclose risks, which could impair future capital raising efforts.
- Legal Action Context: A securities class action against Zoetis alleges that the company misrepresented the risks associated with its products between January 14, 2025, and May 6, 2026, potentially leading to investor losses and increasing legal risks for the firm.
- Disclosure Deficiencies: The lawsuit claims that Zoetis failed to communicate a significant decline in veterinarian prescription intent for Librela following FDA safety warnings, despite management's assertions of “very strong” customer satisfaction, highlighting a lack of transparency in the face of real market challenges.
- Regulatory Letter Impact: The FDA's letter described severe adverse neurological events linked to Librela, yet Zoetis management characterized it as “terribly helpful,” a contradictory statement that may further erode investor trust.
See More
Zoetis Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP reminds investors of a class action filed against Zoetis Inc. (NYSE: ZTS) for securities purchased between January 14, 2025, and May 6, 2026, alleging failure to disclose critical product performance issues that led to investor losses.
- Market Share Decline: The complaint indicates that Zoetis' Librela and Simparica Trio products lost market share due to slowing veterinarian prescription growth, compounded by FDA safety warnings and competition from lower-priced alternatives, adversely affecting the company's core business.
- Deteriorating Financial Results: In its Q1 2026 financial report, Zoetis revealed significant deterioration in its core Companion Animal business and sharply reduced its full-year guidance, resulting in a 21.5% stock price drop on May 7, 2026.
- Investor Action: Affected shareholders can submit documents by July 27, 2026, to serve as lead plaintiffs in the class action, with Robbins LLP offering contingency fee representation, ensuring no upfront costs for shareholders.
See More
